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Transglutaminases (TGases) are calcium-dependent enzymes
catalysing the post-translational cross-linking of proteins. In the
prostate at least two TGases are present, the ubiquitously
expressed tissue-type TGase (TG
C
), and a prostate-restricted
TGase (TG
P
). This paper deals with the molecular cloning and
characterization of the cDNA encoding the human prostate
TGase (hTG
P
). For this purpose we have screened a human
prostate cDNA library with a probe from the active-site region
of TG
C
. The largest isolated cDNA contained an open reading
frame encoding a protein of 684 amino acids with a predicted
INTRODUCTION
Transglutaminases (TGases, EC 2.3.2.13) are calcium-dependent
enzymes that catalyse the acyl transfer reaction between peptide-
bound glutamine residues and primary amine groups. This
reaction results in the post-translational modification of proteins
either by the incorporation of amines (such as polyamines) into
proteins or by the cross-linking of proteins if the amine is a
peptide-bound lysine. The cross-links are resistant to proteolytic
enzyme degradation and thus contribute to the formation of
highly insoluble macromolecules, which can be catabolized only
by proteolysis of the protein chains [1,2].
Products of the enzymic actions of TGases can be found in
most tissues [3] and body fluids [2,4,5]. A number of different
TGases, with different structural properties and cellular origins,
account for the formation of such reaction products. Well
documented examples of TGases are plasma Factor XIIIa [6],
keratinocyte TGase (TG
K
) [7,8], epidermal TGase (TG
E
) [9],
tissue-type or cellular TGase (TG
C
) [10,11] and prostatic TGase
(TG
P
) [5,12–14]. While the physiological functions of Factor
XIIIa (blood clotting), TG
E
and TG
K
(squamous differentiation
of the epidermis by formation of cornified cell envelopes) are
evident, the roles of TG
C
and TG
P
are less well established. The
ubiquitously expressed TG
C
was suggested to be involved in
processes associated with cell growth regulation, differentiation
and programmed cell death [15–17]. This enzyme may take part
in such diverse events as apoptotic body formation [3,18–20],
extracellular matrix stabilization [2,21] and signal transduction
[22]. TG
P
was, until very recently, demonstrated only in rodents.
In these animals, the enzyme is involved in the formation of
copulatory plugs in the female genital tract after coitus [5], and
may play a role in masking the antigenicity of the male gamete,
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molecular mass of 77 kDa as confirmed by in itro transcription–
translation and subsequent SDS}PAGE. The hTG
P
gene was
tissue-specifically expressed in the prostate, yielding an mRNA
of approx. 3.5 kb. Furthermore, a 3-fold androgen-induced up-
regulation of hTG
P
mRNA expression has been demonstrated in
the recently developed human prostate cancer cell line, PC346C.
Other well established human prostate cancer cell lines, LNCaP
and PC-3, showed no detectable hTG
P
mRNA expression on a
Northern blot. The gene coding for prostate TGase was assigned
to chromosome 3.
thereby suppressing an immune response in the female genital
tract against the sperm cells [23,24]. Isolation of the cDNA
encoding rat prostate TGase (rTG
P
) happened to be achieved
when Ho et al. [12] attempted to clone the gene for DP1, an
abundantly expressed rat dorsal prostate protein. DP1 occurred
only in the dorsal rat prostate and the coagulating gland, where
it comprised up to 25% of the total cellular protein, and its
expression was found to be higher in intact than in castrated
animals [12].
Also in the human prostate two types of TGases (TG
C
and
TG
P
) might potentially be expressed. To isolate the human
TGase similar to the rat DP1 enzyme, we have searched for
human TG
P
(hTG
P
) cDNA clones in a human prostate cDNA
library. Here we present the molecular cloning and charac-
terization of hTG
P
cDNA. In addition, this paper deals with
chromosome assignment, organ specificity of hTG
P
expression
and androgenic regulation of hTG
P
in human prostate cancer
cells.
MATERIALS AND METHODS
Cell culture
LNCaP [25] and PC-3 [26] cells were cultured in RPMI medium
supplemented with 7.5% (v}v) fetal-calf serum (FCS) and
antibiotics. The PC346C cell line was recently established in our
laboratory [27]. Cells were cultured in a Dulbecco’s modified
Eagle’s medium (DMEM)}F12-based growth medium (GIBCO,
Grand Island, NY, U.S.A.), essentially as described by Limon et
al. [28], but dihydrotestosterone was replaced by the synthetic
androgen R1881 (NEN, Boston, MA, U.S.A.) and with further
supplementation of 2% (v}v) FCS. The growth of PC346C cells
was stimulated by androgens [27]. To study androgen regulation
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Table 1 Oligonucleotides used for isolation of cDNA clones and chromosomal localization of the hTGP gene
Primer name* Sequence  Length Orientation Source Position Reference
kGT11.for 5-«GGTGGCGACGACTCCTGGAGCC-3« 22-mer Sense kGT11 –
kGT11.rev 5«-GACACCAGACCAACTGGTAATG-3« 22-mer Anti-sense kGT11 –
TRAGLU 1 5«-TA/TTGGCCAGTGCTGGGTTT-3« 19-mer Sense TGC 955–973 [10]
TRAGLU 2 5«-TTC/GACCTCC/GGTGAAG/CACGA-3« 19-mer Anti-sense TGC 1328–1310 [10]
TRAGLU R1 5«-GCTTTGGCCAGTGCTGGGTT-3« 20-mer Sense Rat DP1 820–839 [12]
TRAGLU R2 5«-CACCTCCGTGAACACAAATGT-3« 21-mer Anti-sense Rat DP1 1196–1176 [12]
HPSTG 1 5«-CTCATTCACATAGGTGTCCAC-3« 21-mer Anti-sense hTGP 974–954 This paper
HPSTG 2 5«-TCATAGCACACATGGCCCT-3« 19-mer Anti-sense hTGP 702–684 This paper
* GT11.for and GT11.rev represent the flanking GT11 primers used for PCR.
 TRAGLU 1 and TRAGLU 2 are degenerated primers as is indicated by a slash.
of gene expression, the cells were cultured in the absence and
presence of 0.1 nM R1881 in growth medium containing dextran–
charcoal-treated (DCC) serum. The cells were harvested from
near-confluent cultures (after 7 days for LNCaP and 10 days for
PC346C), and subjected to RNA isolation as described below.
Screening of a human prostate cDNA library
For the isolation of hTG
P
, an oligo(dT) and random-primed
kgt11 human prostate cDNA library (Clontech, Palo Alto, CA,
U.S.A.) was screened with a random $#P-labelled 380 bp probe
from the active-site region of TG
C
. This probe was obtained by
PCR amplification with primer TRAGLU 1 and TRAGLU 2
(see Table 1 for list of primers) of this area from pSG5.hTG, a
plasmid containing the entire cDNA sequence of human TG
C
,
which was kindly provided by Dr. P. J. A. Davies [11].
Hybond-N­ filters (Amersham, Aylesbury, Bucks., U.K.)
were prehybridized with 100 lg}ml denatured salmon sperm
DNA in poly(ethylene glycol) (PEG)-hybridization mix, com-
posed of 0.25 M Na
#
HPO
%
,2H
#
O (pH 7.2), 0.25 M NaCl, 7%
(w}v) SDS, 10% PEG 6000 and 1 mM EDTA, for 2 h. Hybrid-
izations were carried out overnight at 50 °C, followed by two
washes with 2¬SSC}0.1% SDS and two washes with
1¬SSC}0.1% SDS, each for 15 min at 50 °C (1¬SSC: 0.15 M
NaCl}0.015 M sodium citrate). Washed blots were covered with
plastic film and exposed to RX medical X-ray film (Fuji) with
intensifying screen for 4 days at ®80 °C.
Positive plaques were picked up and rescreened at least twice
until the selected plaques were completely purified. The inserts of
these clones were amplified by PCR (see below), and directly
sequenced with primer TRAGLU R2 (Table 1). The selected
phage clone was purified and treated as described below under
‘DNA sequencing’. Since this procedure resulted in the isolation
of a clone containing only part of the hTG
P
cDNA sequence (see
the Results section), a 2.2 kb SacI–HpaI fragment of this clone
was used as a probe to rescreen the same cDNA library under
more stringent conditions with the purpose of isolating the entire
hTG
P
cDNA. Hybridizations and washes were performed at
65 °C instead of 50 °C. Selected recombinant phage clones were
purified and treated as described below.
PCR amplification and primer removal
PCR amplifications of phage suspension aliquots, or of isolated
DNA, were performed with superTaq polymerase (Sphaero Q,
HT Biotechnology, U.K.) in the presence of 100 ng of each
primer. All samples were first denatured at 94 °C for 5 min.
Amplification followed in 35 cycles of 94 °C, 1 min; 55 °C,
1 min; 72 °C, 2 min; and a final extension at 72 °C for 10 min.
PCR products were analysed by agarose gel electrophoresis. If
necessary, primers were removed with the QIAquick PCR
purification kit (Qiagen, Hilden, Germany).
DNA sequencing
DNA was isolated from the selected and purified recombinant
phage clones following standard procedures [29] and the cDNA
fragments were subcloned into the EcoRI site of pGEM-7Zf(­)
(Promega, Madison, WI, U.S.A.) for sequencing. Plasmid iso-
lations were performed with a Qiagen plasmid kit. Double-
stranded DNA sequence analysis was performed by dideoxy-
nucleotide chain termination using a T7 sequencing kit
(Pharmacia, LKB Biotech, Uppsala, Sweden). Oligonucleotide
primers used for walking primer sequencing were designed and
synthesized on the basis of the obtained sequences (Pharmacia).
In vitro transcription–translation of hTGP and TGC cDNA
For in itro transcription–translation studies the entire open
reading frame of hTG
P
cDNA was subcloned into the eukaryotic
expression vector pcDNA3 (Invitrogen Corporation, San Diego,
CA, U.S.A.). For comparison the entire 3.3 kb cDNA for TG
C
[11] was subcloned into the EcoRI site of pcDNA3 (pcDNA3-
TG
C
). An empty pcDNA3 vector was used as a negative control.
Subsequently, a one-tube, coupled transcription–translation was
performed with the TNT2 coupled reticulocyte lysate system
from Promega using the T7 RNA promoter present in pcDNA3
for in itro transcription of sense RNA. The reactions were
performed on 1 lg of circular template DNA in a final volume of
25 ll accordingtothemanufacturer’sprotocol.Thetranscription–
translation was carried out at 30 °C for 90 min in the presence of
$&S-labelled methionine (Amersham, Aylesbury, Bucks., U.K.).
Labelled products were separated by SDS}10%-PAGE. The gel
was dried and the synthesized proteins were visualized by
exposure to RX medical X-ray film (Fuji) for 4 h. Prestained
markers (Novex, San Diego, CA, U.S.A.) were used as size
standards.
Northern hybridization
Isolation of total RNA was carried out by the guanidine
isothiocyanate}caesium chloride centrifugation method [29].
Total RNA (20 lg) was electrophoresed in a 1% agarose
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formaldehyde gel and transferred to Hybond N­. RNA was
fixed to the membrane by UV cross-linking. The blot was
hybridized overnight at 60 °C with the 2.2 kb probe mentioned
above in hybridization mix composed of 0.5 M Na
#
HPO
%
,2H
#
O
(pH 7.2), 7% SDS, 1% BSA and 1 mM EDTA. The final wash
step was in 0.3¬SSC}0.1% SDS at 60 °C for 30 min. The blot
was exposed to RX medical X-ray film (Fuji) with intensifying
screen for 4 days at ®80 °C. The signals were quantified on a
PhosphorImager (Molecular Dynamics, Sunnyvale, CA, U.S.A.).
A human multiple-tissue Northern blot (MTN II, Clontech)
was used to determine the tissue specificity of hTG
P
expression.
Hybridization was performed with the same cDNA fragment as
above using conditions recommended by the manufacturer.
Washes were performed under high-stringency conditions (up to
0.1¬SSC}0.1% SDS at 63 °C for 30 min). The integrity of the
blotted RNA was determined by hybridization with human b-
actin cDNA.
Chromosomal localization of the gene encoding hTGP
A human}hamster–human}mouse somatic cell hybrid panel
(BIOS Research Laboratories, New Haven, CT, U.S.A.) was
screened by PCR analysis with the HPSTG1–TRAGLU R1
primer set (Table 1). PCR reactions were performed on 50 ng of
somatic cell hybrid DNAs as described above. An annealing
temperature of 60 °C was used. The resulting products were
analysed by agarose gel electrophoresis. The specificity of the
reaction products was confirmed by blotting and subsequent
hybridization with a $#P random-labelled 2.2 kb SacI–HpaI hTG
P
fragment. Hybridization and washes were as described above for
Northern hybridization.
RESULTS
Isolation of cDNA clones
Screening under low-stringency conditions of approx.
1.2¬10' p.f.u. of a kgt11 human prostate cDNA library with a
380 bp fragment from the active-site region of TG
C
yielded nine
positive clones. Partial sequence analysis with primer TRAGLU
R2 (Table 1) in the vicinity of the active site revealed that one
clone (4.2) had high sequence similarity to rat DP1 [12]. The
insert size was approx. 2.8 kb. The other clones appeared to be
parts of TG
C
cDNA. Sequence analysis of the entire insert of
clone 4.2 showed an open reading frame encoding a protein of
574 amino acids. Comparison with the amino acid sequences of
other TGases suggested that part of the 5« end of the hTG
P
cDNA was missing, probably due to a cloning artefact. To
obtain further cDNA information, the same prostate cDNA
library was rescreened under high-stringency conditions with the
2.2 kb SacI–HpaI fragment from clone 4.2 (see Figure 1 for
restriction map). This resulted in a large number of positive
plaques (about 500) of which 24 were isolated. As our main
interest concerned the 5« end of the hTG
P
cDNA, a further
selection was made by PCR with combinations of primer HPSTG
1 or HPSTG 2 and one of the flanking kgt11 primers. In this way,
three overlapping clones, clones 1.8, 1.12 and 1.17, were selected
with inserts varying from 2.4 kb to 3.3 kb. The relative positions
of the cDNAs of these clones are shown in Figure 1. EcoRI
fragments of the three clones were sequenced. Whereas clone 4.2
appeared to lack a coding region for 130 amino acids at its N-
terminus, both clone 1.8 and clone 1.17 contained the entire open
reading frame of hTG
P
cDNA. Further analysis showed a number
of cloning artefacts (see Figure 1). Clone 1.17 contained ampli-
fications of central parts of the hTG
P
cDNA sequence at its 5«
and 3« terminal ends, and 1.12 appeared to have a 5« nucleotide
stretch similar to that of clone 4.2 but situated more to the 5«-
end.
cDNA sequence of hTGP
Figure 2 shows the composite nucleotide sequence of the hTG
P
cDNA as well as its deduced amino acid sequence. Its total
length is 2983 bp with an open reading frame that corresponds to
a protein of 684 amino acids with a predicted molecular mass of
77 kDa and a pI of 6.94.
Two start codons are present at the beginning of the open
reading frame, preceded by an in-frame stop codon. Which one
of the start codons is used for translational start cannot be
deduced from the sequence. However, the DNA sequence sur-
rounding the second methionine agrees well with the Kozak
consensus sequence [30] with an A at position ®3 and a G in
position ­4 (as the A of the ATG codon is designated ­1). The
3« non-coding region of hTG
P
cDNA contains the variant
polyadenylation signal, ATTAAA (Figure 2) [31].
The active-site amino acid sequence GQCWVF (residues
266–271) is present, suggesting that the clone encodes for an
active TGase. Also other amino acids recently shown to be
crucial for catalytic activity of TGases, but not part of the active
centre, are present. These amino acids, Arg-37 (R), Arg-38 (R)
[32,33], His-296 (H), His-327 (H) and Asp-350 (D) [34], occur in
all human TGases. The amino acid sequence shows no typical
Ca#+-binding-site motif, like an EF-hand structure, but two
regions enriched with acidic residues (residues 144–154 and
433–453) may reflect Ca#+-binding sites. In addition, the putative
hTG
P
protein has seven potential N-glycosylation sites (sites are
indicated in Figure 2).
In vitro transcription–translation of hTGP and TGC cDNA
To verify whether the isolated cDNA was able to produce a
protein product and whether the size of the encoded protein
corresponds to its predicted molecular mass, the entire coding
regionofhTG
P
wascloned intopcDNA3for initro transcription–
translation. For this purpose, we first subcloned the 3«
EcoRI–EcoRI fragment of the largest clone, clone 1.17 (Figure
1), into the EcoRI site of pcDNA3. Subsequently, removal of the
3« EcoRI site (including the 3« artefact of clone 1.17) was
achieved by cleavage with HpaI (insert) and XbaI (vector).
Because of the presence of a 5« artefact in clone 1.17 (see above),
we used the 5« 184 bp EcoRI–EcoRI fragment from clone 1.8 for
ligation to the EcoRI–HpaI fragment of clone 1.17. In this way
the entire coding region of hTG
P
was cloned into pcDNA3
(pcDNA3-hTG
P
) with only three nucleotides left in front of its
start codon.
Figure 3 shows that both pcDNA3-hTG
P
and pcDNA3-TG
C
produced a single protein. The molecular mass of the hTG
P
protein was established to be approx. 77 kDa which is in
agreement with its predicted molecular mass. The TG
C
construct
yielded a protein of approx. 85 kDa which size is somewhat
larger than its predicted molecular mass of 77 kDa. This ob-
servation is in agreement with the in itro translation results of
Gentile et al. [10]. The control plasmid produced no protein
bands.
Expression of hTGP in the prostate and in prostate-derived cell
lines
To determine the expression pattern of hTG
P
a human multiple-
tissue Northern blot with poly(A)+ RNA from eight different
tissues including prostate was hybridized under high stringency
conditions with a 2.2 kb SacI–HpaI fragment from clone 4.2. As
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Figure 1 Restriction map and relative positions of cDNA clones for hTGP
Black bars represent coding regions. Cloning artefacts are indicated by broken black bars.
Clones 4.2 and 1.12 contained at their 5« ends the same artificial nucleotide sequence but at
different positions. Clone 1.17 contained amplifications of central parts of the hTGP cDNA at its
terminal ends. Clone 1.8 had only three nucleotides in front of its start codons.
shown in Figure 4 hTG
P
mRNA was exclusively expressed in the
prostate. A single mRNA was detected with a length of approx.
3.5 kb. Prolonged exposure of the Northern blot did not result in
a positive signal in either of the other tissues tested. The hTG
P
mRNA could be clearly distinguished from the approx. 4 kb TG
C
mRNA as was determined by Northern-blot analysis of total
RNA from benign prostate hyperplasia tissue (results not shown).
Next it was investigated whether hTG
P
was also expressed in
prostate cancer cell lines. For this purpose we performed
Northern-blot analysis of totalRNA from thewell-known human
prostate carcinoma cell line LNCaP as well as from a prostate
cancer cell line, PC346C, recently developed in our laboratory
[27] (see the Materials and methods section). While no hTG
P
mRNA could be detected in LNCaP, PC346C expressed one
mRNA of the same length (3.5 kb) as has been found in prostatic
tissue. The Northern blot results for LNCaP and PC346C are
shown in Figure 5. We could not detect hTG
P
mRNA in the
androgen-independent cell line PC-3 [26] (results not shown).
Androgen-regulated expression of hTGP
To investigate androgen regulation of hTG
P
expression, we used
the androgen-responsive prostate cancer cell lines LNCaP and
PC346C. Both cell lines were grown in the presence or absence of
0.1 nM R1881. Northern-blot analysis of total RNA from treated
and untreated cells, using the 2.2 kb SacI–HpaI fragment from
clone 4.2 as probe, showed that in PC346C cells the amount of
hTG
P
mRNA was 3-fold increased in the presence of R1881,
demonstrating that the hTG
P
expression can be up-regulated by
androgen. However, even after induction with R1881, no hTG
P
mRNA could be visualized in the LNCaP cells (Figure 5). The
same blot was also hybridized with a probe for TG
C
, but neither
in LNCaP nor in PC346C cells was TG
C
expression detected.
Chromosomal localization of the hTGP gene
Chromosomal localization of the gene encoding hTG
P
was
performed by screening by PCR a panel of 20 human}hamster
and human}mouse somatic-cell-hybrid cell lines that contain
each of the human chromosomes in one or more of the hybrid
DNAs (Figure 6). For this approach the primer pair
HPSTG1–TRAGLU R1 was used (Table 1).
PCR analysis on chromosomal DNA isolated from PC346C
cells (results not shown) resulted in a product of 250 bp, while
PCR on hTG
P
cDNA would have yielded a product of 150 bp
(see Table 1). This difference in size is most probably due to the
presence of an intron of approx. 100 bp in this part of the gene.
Comparison with the organization of other TGase genes in that
region is in favour of this assumption (see Kim et al. [35]).
Figure 2 Nucleotide and deduced amino acid sequence of hTGP cDNA
The deduced amino acid sequence is numbered from the first methionine. The active-site
sequence GQCWVF is bold-typed and the active-centre cysteine is marked with an asterisk. A
putative polyadenylation signal is double-underlined. An in-frame stop codon preceding the start
codons is indicated by a closed circle. Two putative Ca2+-binding regions are underlined.
Potential N-glycosylation signals (N-X-S/T) are indicated by closed triangles. The sequence
deviates at several positions from the sequence recently published by Grant et al. [54]. A
remarkable difference was found at positions 338–342 of the deduced amino acid sequence.
In all four isolated clones we here found an insertion of the five amino acids DLPKG, which
is also present at this position in all other TGases. Other amino acid substitutions were found
at positions K313E, R466Q and F584N. In addition, the 23 nucleotides at the 3«-terminal end
were found to be different (similar in clones 4.2, 1.12 and 1.17).
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Figure 3 In vitro transcription–translation of hTGP and TGC cDNA
The entire open reading frames of the cDNAs encoding hTGP (pcDNA3-hTGP) and TGC (pcDNA3-
TGC) were subcloned into the eukaryotic expression vector pcDNA3. One lg of each vector was
used for a one-tube in vitro transcription–translation reaction. As a control pcDNA3 without
insert (®) was used. Protein products were separated by SDS/10%-PAGE. On the left-hand
side the molecular mass of the translated proteins and of the molecular mass standards are
indicated.
Figure 4 Northern-blot analysis of hTGP expression in human tissues
A human multiple-tissue Northern blot was hybridized under high-stringency conditions (see
the Materials and methods section) with a random 32P-labelled 2.2 kb Sac I–Hpa I fragment from
clone 4.2. Each lane contained 2 lg of poly(A+) RNA. The integrity of the blot was determined
by hybridization with human b-actin cDNA.
As presented in Figure 6 only the presence or absence of
human chromosome 3 is concordant with the presence of a PCR
product, whereas at least two discordancies were observed for all
other chromosomes. The authenticity of the obtained 250 bp
products was proven by hybridization with the 2.2 kb SacI–HpaI
fragment from clone 4.2. No cross-reactivity was found with
hamster or mouse chromosomal DNA present in the DNA
hybrids.
DISCUSSION
In this paper, we describe the molecular characterization of the
cDNA encoding a prostate TGase, hTG
P
. The composite cDNA
Figure 5 Androgen-regulated expression of hTGP mRNA
Northern-blot analysis of PC346C and LNCaP grown in the presence (­) or absence (®) of
0.1 nM of the synthetic androgen R1881 and further treated as described in the Materials and
methods section. Each lane contains 20 lg of total RNA. The blot was hybridized under high-
stringency conditions (see the Materials and methods section) with a random 32P-labelled
2.2 kb Sac I–Hpa I fragment from clone 4.2. Hybridization with a b-actin probe was performed
as a control.
Figure 6 Assignment of the hTGP gene to human chromosome 3
A panel of human/hamster and human/mouse somatic cell hybrid DNAs was screened by PCR
with the HPSTG1–TRAGLU R1 primer set (see Table 1). PCR products generated by this primer
pair were separated on a 1% agarose gel (results not shown). DNA was amplified from somatic
hybrid cell lines (cell line designations are indicated at the top of the Figure), as well as human,
hamster and mouse genomic DNA. The Figure shows correlation between the presence of
human chromosomes in the somatic cell line panel (as described by the manufacturer), and the
presence or absence of a specific PCR product. On the left-hand side the human chromosome
number is indicated. The somatic cell lines in which a specific PCR product could be detected
are indicated in the lower bar by the shaded areas. Percentage discordance is shown at the
right. Assignment of the hTGP gene to chromosome 3 had a discordance of 0%, while all other
human chromosomes were excluded by & 10% discordance. Symbols : an asterisk indicates
human/mouse somatic cell hybrid, all others are human/hamster hybrids ; D, multiple deletions ;
­, " 30% of the cells contain the given chromosome ; ³, 5–30% of the cells contain the
given chromosome.
sequence consists of 2983 nucleotides, containing an open reading
frame encoding a protein of 684 amino acids. The deduced
amino acid sequence contains significant similarity with other
members of the human TGase family (Figure 7). Especially in the
region of the active site these sequences display a high degree of
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Figure 7 Comparison of the deduced amino acid sequence of hTGP with other human TGases
HTGASEP, K, C, 3 and HFXIIIA represent hTGP, TGK [55], TGC [10], TGE [9], and plasma Factor XIIIa [56], respectively. Bold-type residues represent amino acids present in all sequences. Hyphens
indicate identities with the amino acids of hTGP. Dots represent gaps introduced for optimal alignment. Closed triangles indicate amino acids, mentioned in the text, important for the catalytic function
of TGases.
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similarity not only concerning the deduced primary amino acid
sequences, but also the hydrophobicity directly C-terminal to the
active site [6,7]. The amino acid sequences of hTG
P
and rTG
P
share an identity of 53%. The overall identity of hTG
P
with the
other TGases is approx. 30%. The degree of similarity is very
low C-terminal to the putative Ca#+-binding site at positions
433–453. Essential amino acids are present in the deduced amino
acid sequence, such as the active-site cysteine which is an absolute
prerequisite for TGase activity as well as the amino acids directly
surrounding this cysteine [34]. Also, other amino acids which
are away from the active centre in the primary sequence but are
required for catalytic function of TGases, because of their
putative influence on the protein conformation, are present
[32–34]. Together, these results suggest that we have isolated a
cDNA encoding an active prostatic TGase.
We assigned the gene encoding hTG
P
unambiguously to
chromosome 3. No other human genes encoding TGases known
so far are localized on this chromosome. The other TGase genes
are assigned to chromosome bands 6p24-p25, Factor XIIIa [36],
14q11.2-q13, TG
K
[37], and TG
C
as well as TG
E
to 20q11.2-
20q12 [38,39]. While this paper was in preparation, a report by
Gentile et al. confirmed our results by sublocalizing the hTG
P
gene to chromosome band 3p21.33-p22 [40].
In itro transcription–translation of hTG
P
cDNA demon-
strated that the core protein without any post-translational
modifications behaves as a protein of approx. 77 kDa on
SDS}PAGE, which is slightly larger than the 65 kDa rat DP1
[12,41]. Results of Seitz and co-workers [42,43] suggested that a
protein of about the same molecular mass, with cross-reactivity
to an antibody against rTG
P
, is present in human semen.
The putative hTG
P
protein contains seven N-glycosylation
consensus sequences distributed over the entire protein. Four of
these are at identical sites in hTG
P
and rTG
P
. However, this does
not necessarily result in glycosylation at these sites. Both TG
C
and Factor XIIIa contain several potential N-glycosylation sites,
but no glycosylation has been observed [1,6]. In the rat, TG
P
was
reported to be glycosylated [12,13] and to contain a glyco-
sylphosphatidylinositol (GPI) anchor which may protect the
protein from autoaggregation [13]. Until now, the identified
GPI-anchored proteins were demonstrated to contain a hydro-
phobic sequence at their C-terminal sequence [44]. Based upon
these results one would not expect a GPI-anchor for either rTG
P
or hTG
P
, because of the lack of a hydrophobic stretch of amino
acids at their C-terminus. It cannot be excluded, however, that
for the attachment of the GPI-anchor to rTG
P
other sequence
determinants might be used. It would be of interest to know
whether hTG
P
is also glycosylated and has a protective GPI-
anchor.
Androgens are essential for the growth and maintenance of
prostate tissue and control the formation of prostatic secretions.
Immunohistochemical and mRNA studies have shown that
RatDP1 or rTG
P
is androgen-regulated [12,45]. The expression
of rTG
P
was demonstrated to be restricted to the dorsal lobe of
the prostate and the coagulation gland. Expression of the hTG
P
gene leads to an mRNA of approx. 3.5 kb both in prostatic tissue
and in the androgen-responsive prostate cancer cell line PC346C.
The androgen-independent prostate cancer cell line PC-3 (results
not shown) as well as the androgen-responsive prostate car-
cinoma cell line LNCaP showed no expression of hTG
P
mRNA
as determined by Northern-blot hybridization. As far as the
tissues tested are concerned, hTG
P
is exclusively expressed in the
prostate. Presently we are examining a more extended number of
tissues to confirm prostate-specificity of hTG
P
expression.
Androgen-dependent expression of hTG
P
was observed in
PC346C cells. The level increased 3-fold in the presence of
0.1 nM of the synthetic androgen R1881. The question remains
open as to whether the androgen-up-regulated expression of
hTG
P
is due to a direct regulation at the transcriptional level or
is a consequence of stabilization of the mRNA. Indirect evidence
obtained by Ho et al. [12] suggests that the latter is the case for
rTG
P
and that androgen acts through prolongation of the rTG
P
mRNA half-life. At present, only a few human genes have been
described, for example the prostate-specific genes human glandu-
lar kallikrein-1 and prostate-specific antigen (PSA), as being
under androgenic control at the transcriptional level. Both human
glandular kallikrein-1 and PSA contain androgen-responsive
elements in their promoters [46,47]. Kinetic studies of the
androgen-regulated expression of hTG
P
mRNA and isolation
and characterization of the promoter region of hTG
P
may
elucidate at which level androgens regulate its expression.
Additionally, comparison of the promoter regions of genes
specifically expressed in the prostate may give some clues to
tissue-specific regulatory elements.
Unlike hTG
P
, TG
C
is up-regulated by androgen withdrawal in
the rat ventral prostate [48]. However, this may be an indirect
consequence of the induction of the apoptotic pathway by
removal of androgens from the circulation.
In contrast to rTG
P
, for which there is a very obvious function
in the formation of the copulatory plug [5], little is known about
the physiological role of hTG
P
. Most likely the function of hTG
P
is in semen. However, in contrast to PSA, for example, which is
also excreted by the prostate, the deduced protein sequence does
not contain an obvious signal sequence for excretion [46]. The
same is true for rTG
P
[12]. For this protein evidence has been
obtained that secretion might occur via an alternative pathway
[45], which is also suggested for two other TGases, Factor XIIIa
and TG
C
[2]. Some effort has been made to obtain evidence for
the presence and function of hTG
P
in human semen. A report of
Lilja and Laurell [49] suggests that, in contrast to rat seminal
clotting, TGase activity may not be essential for human semen
coagulation. They hypothesized that, besides disulphide bridges
in particular, non-covalent protein interactions are important for
the clot structure. In addition, they did not find TGase activity
in human semen, while Porta et al. [50] demonstrated TGase
activity in human seminal plasma of normal individuals. Others
found only TGase activity in infertile patients with semen having
prolonged liquefaction time [42,43]. Besides a role of hTG
P
in
coagulation, it may function in suppressing the sperm surface
antigenicity, thereby preventing an immunological response in
the female genital tract. Suppression of antigenicity through the
involvement of the cross-linking activity of TGase has been
reported for rat and rabbit, as well as for human sperm [23,24,51].
At last, an intracellular role of hTG
P
cannot be excluded.
Presently, prostate cancer is the most common cancer in the
male population of the U.S.A. and Europe. A main problem in
the treatment of clinically localized prostate cancer is the presence
of micrometastasis at the time of radical prostatectomy [52].
Monitoring the presence of prostate cancer cells in tissues and
blood before and after treatment may offer the possibility to
optimize treatment methods [53]. Given its prostate-restricted
expression, as suggested by our results, hTG
P
may represent a
valuable alternative to PSA as a marker for detection of prostate
cancer cells, for instance by reverse-transcription PCR analysis.
We are interested in prostatic TGases and their possible role in
the regulation of human prostate tumour growth and metastasis
(TG
C
) and their usefulness as differentiation or tumour markers
(hTG
P
) in prostate cancer. The isolation of the cDNA for hTG
P
and some first clues to the specificity and regulation of its
expression may help us to discriminate between the prostatic
TGases, and to get more insight into the putative function(s) of
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the hTG
P
protein. Currently, antisera against the C-terminal
region of either hTG
P
or TG
C
are being generated to enable us to
discriminate at the protein level as well.
We are indebted to Mrs. Sigrun Erkens-Schulze and Mrs. Wilma Teubel for cell
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Veldscholte for using their cDNA library filters and for assistance during library
screening. We would like to thank Dr. P. J.A. Davies for supplying us with TGC cDNA.
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